[{"orgOrder":0,"company":"89bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"BIO89-100","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"89bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"89bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"89bio \/ Not Applicable"},{"orgOrder":0,"company":"89bio","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Public Offering","leadProduct":"BIO89-100","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"89bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"","sponsorNew":"89bio \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"89bio \/ BofA Securities"},{"orgOrder":0,"company":"89bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"BIO89-100","moa":"FGF21","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"89bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"89bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"89bio \/ Not Applicable"},{"orgOrder":0,"company":"89bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"BIO89-100","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"89bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"","sponsorNew":"89bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"89bio \/ Not Applicable"},{"orgOrder":0,"company":"89bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"BIO89-100","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"89bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"89bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"89bio \/ Not Applicable"},{"orgOrder":0,"company":"89bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"BIO89-100","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"89bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"89bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"89bio \/ Not Applicable"},{"orgOrder":0,"company":"89bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"BIO89-100","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"89bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"89bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"89bio \/ Not Applicable"},{"orgOrder":0,"company":"89bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"BIO89-100","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"89bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"89bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"89bio \/ Not Applicable"},{"orgOrder":0,"company":"89bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"TEV 47948","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"89bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"89bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"89bio \/ Not Applicable"},{"orgOrder":0,"company":"89bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"TEV 47948","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"89bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"89bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"89bio \/ Not Applicable"},{"orgOrder":0,"company":"89bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Pegozafermin","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"89bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"89bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ Not Applicable"},{"orgOrder":0,"company":"89bio","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Public Offering","leadProduct":"Pegozafermin","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"89bio","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0.089999999999999997,"dosageForm":"Injectable\/Injection","sponsorNew":"89bio \/ BofA Securities","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ BofA Securities"},{"orgOrder":0,"company":"89bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Pegozafermin","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"89bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"89bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ Not Applicable"},{"orgOrder":0,"company":"89bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Pegozafermin","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"89bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"89bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"89bio \/ Not Applicable"},{"orgOrder":0,"company":"89bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Pegozafermin","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"89bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"89bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ Not Applicable"},{"orgOrder":0,"company":"89bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Pegozafermin","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"89bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"89bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ Not Applicable"},{"orgOrder":0,"company":"89bio","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"Pegozafermin","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"89bio","amount2":0.28000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0.089999999999999997,"dosageForm":"Injectable\/Injection","sponsorNew":"89bio \/ BofA Securities","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ BofA Securities"},{"orgOrder":0,"company":"89bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Pegozafermin","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"89bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"89bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ Not Applicable"},{"orgOrder":0,"company":"89bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Pegozafermin","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"89bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"89bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ Not Applicable"},{"orgOrder":0,"company":"89bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Pegozafermin","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"89bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"89bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ Not Applicable"},{"orgOrder":0,"company":"89bio","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"Pegozafermin","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"89bio","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.17000000000000001,"dosageForm":"Injection","sponsorNew":"89bio \/ BofA Securities","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ BofA Securities"},{"orgOrder":0,"company":"89bio","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"Pegozafermin","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"89bio","amount2":0.17000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.17000000000000001,"dosageForm":"Injection","sponsorNew":"89bio \/ BofA Securities","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ BofA Securities"},{"orgOrder":0,"company":"89bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Pegozafermin","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"89bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"89bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ Not Applicable"},{"orgOrder":0,"company":"89bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Pegozafermin","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"89bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"89bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ Not Applicable"},{"orgOrder":0,"company":"89bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Pegozafermin","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"89bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"89bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ Not Applicable"},{"orgOrder":0,"company":"89bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Pegozafermin","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"89bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"","sponsorNew":"89bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ Not Applicable"},{"orgOrder":0,"company":"89bio","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Public Offering","leadProduct":"Pegozafermin","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"89bio","amount2":0.13,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0.13,"dosageForm":"","sponsorNew":"89bio \/ Goldman Sachs & Co","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"89bio","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2025","type":"Public Offering","leadProduct":"Pegozafermin","moa":"FGF21R","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"89bio","amount2":0.25,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0.28999999999999998,"dosageForm":"Subcutaneous Injection","sponsorNew":"89bio \/ Goldman Sachs & Co","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"89bio","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2025","type":"Public Offering","leadProduct":"Pegozafermin","moa":"FGF21R","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"89bio","amount2":0.25,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0.28999999999999998,"dosageForm":"Subcutaneous Injection","sponsorNew":"89bio \/ Goldman Sachs & Co","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"89bio","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2025","type":"Public Offering","leadProduct":"Pegozafermin","moa":"FGF21R","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"89bio","amount2":0.28999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0.28999999999999998,"dosageForm":"Subcutaneous Injection","sponsorNew":"89bio \/ Goldman Sachs & Co","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ Goldman Sachs & Co"}]
Find Clinical Drug Pipeline Developments & Deals by 89bio
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
